Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by State Street Corp

State Street Corp trimmed its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 50.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 892,743 shares of the company’s stock after selling 896,446 shares during the period. State Street Corp owned 1.64% of Voyager Therapeutics worth $5,223,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Victory Capital Management Inc. grew its stake in Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after acquiring an additional 1,630 shares in the last quarter. Hunter Perkins Capital Management LLC grew its position in shares of Voyager Therapeutics by 3.3% in the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock valued at $375,000 after purchasing an additional 2,025 shares in the last quarter. Empowered Funds LLC increased its holdings in shares of Voyager Therapeutics by 5.4% in the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock valued at $262,000 after purchasing an additional 2,278 shares during the last quarter. Federated Hermes Inc. lifted its position in Voyager Therapeutics by 0.5% during the second quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock worth $4,384,000 after buying an additional 2,638 shares in the last quarter. Finally, ClariVest Asset Management LLC boosted its stake in Voyager Therapeutics by 2.7% during the second quarter. ClariVest Asset Management LLC now owns 102,822 shares of the company’s stock worth $813,000 after buying an additional 2,699 shares during the last quarter. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $5.74 on Monday. The firm has a 50 day moving average price of $6.31 and a 200 day moving average price of $6.97. Voyager Therapeutics, Inc. has a fifty-two week low of $5.19 and a fifty-two week high of $11.72. The company has a market capitalization of $313.55 million, a PE ratio of 8.08 and a beta of 0.90.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. During the same period in the previous year, the firm posted ($0.59) earnings per share. As a group, equities research analysts forecast that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the transaction, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Citigroup started coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They set a “buy” rating and a $12.00 target price on the stock. Leerink Partners began coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target for the company. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $17.00.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.